{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:49:10Z","timestamp":1782467350569,"version":"3.54.5"},"reference-count":68,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Amyloid positron emission tomography (PET) has become a critical tool in the diagnosis and treatment of Alzheimer\u2019s disease (AD). The Centiloid (CL) scale, a tracer\/scanner-independent, standardized quantification unit introduced in 2015, transforms tracer- and scanner-specific standardized uptake value ratios (SUVRs) into a common metric anchored at 0 CL in young cognitively unimpaired individuals and 100 CL in patients with mild-to-moderate AD. This review synthesizes current evidence on the clinical role of the CL scale across three domains: (1) diagnostic classification, with established thresholds of &lt;10 CL for amyloid negativity and &gt;30 CL for high-certainty amyloid positivity; (2) treatment eligibility, where a 2024 Alzheimer\u2019s Association Research Roundtable consensus of global experts recommended a 24\u201330 CL threshold for initiating lecanemab or donanemab therapy in patients with mild cognitive impairment (MCI) or mild AD dementia; and (3) longitudinal therapy monitoring, in which serial CL measurements provide objective evidence of amyloid clearance. We also review the emerging \u2018gray zone\u2019 (10\u201330 CL) as a distinct clinical entity with elevated progression risk, the critical role of CL quantification in complementing visual reads in borderline cases, technical limitations, and the future integration of CL in clinical practice. This review also critically addresses the ongoing debate on whether amyloid clearance represents a reliable surrogate for clinical benefit, strategies for managing discordant biomarker findings, and the practical feasibility of serial amyloid PET in routine care. With FDA approval of both lecanemab and donanemab, familiarity with the CL scale as a functional treatment biomarker is increasingly relevant for neuroradiologists and nuclear medicine physicians in the modern AD care pathway. As with all imaging modalities, the CL has physiologic and technical limitations. Although the CL scale was designed to reduce heterogeneity across tracers and scanner platforms, the impact of different commercial quantification software packages on CL output remains incompletely characterized. Consistent use of a single software platform for longitudinal monitoring in individual patients is therefore recommended.<\/jats:p>","DOI":"10.3390\/diagnostics16131989","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:43:57Z","timestamp":1782463437000},"page":"1989","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer\u2019s Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective"],"prefix":"10.3390","volume":"16","author":[{"given":"Houman","family":"Sotoudeh","sequence":"first","affiliation":[{"name":"Neuroradiology Section, Department of Radiology, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Neurology, Faculty of Medicine, The University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Liu, W., Deng, W., Gong, X., Ou, J., Yu, S., and Chen, S. (2025). Global Burden of Alzheimer\u2019s Disease and Other Dementias in Adults Aged 65 Years and over, and Health Inequality Related to SDI, 1990-2021: Analysis of Data from GBD 2021. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-22378-z"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100395","DOI":"10.1016\/j.tjpad.2025.100395","article-title":"Reinventing \u201cN\u201d in the A\/T\/N Framework: The Case for Digital","volume":"13","author":"Au","year":"2026","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/WCO.0000000000001462","article-title":"Integration over Reduction: Multimodal PET and Fluid Biomarkers in Alzheimer\u2019s Disease and Beyond","volume":"39","author":"Bluma","year":"2026","journal-title":"Curr. Opin. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/WCO.0000000000001471","article-title":"Clinical Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer\u2019s Disease: Image Interpretation in the Era of Anti-Amyloid Therapies","volume":"39","author":"Mathoux","year":"2026","journal-title":"Curr. Opin. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13550-025-01276-w","article-title":"Head to Head Comparison of Two PET\/CT Imaging Agents, [18F]D3FSP ([18F]P16-129) and [18F]AV45, in Patients with Alzheimer\u2019s Disease","volume":"15","author":"Alexoff","year":"2025","journal-title":"EJNMMI Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate Use Recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing Quantitative Amyloid Plaque Estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid Recommendations for Clinical Context-of-Use from the AMYPAD Consortium","volume":"20","author":"Collij","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2017.08.007","article-title":"APP\/A\u03b2 Structural Diversity and Alzheimer\u2019s Disease Pathogenesis","volume":"110","author":"Roher","year":"2017","journal-title":"Neurochem. Int."},{"key":"ref_11","unstructured":"Frontiers (2026, April 13). In 2024, the Amyloid-Cascade-Hypothesis Still Remains a Working Hypothesis, No Less but Certainly No More. Available online: https:\/\/www.frontiersin.org\/journals\/aging-neuroscience\/articles\/10.3389\/fnagi.2024.1459224\/full."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","article-title":"The Evolution of Preclinical Alzheimer\u2019s Disease: Implications for Prevention Trials","volume":"84","author":"Sperling","year":"2014","journal-title":"Neuron"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1002\/alz.14036","article-title":"Spatial Extent as a Sensitive Amyloid-PET Metric in Preclinical Alzheimer\u2019s Disease","volume":"20","author":"Farrell","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET Imaging to Detect Amyloid Beta Plaques in Alzheimer\u2019s Disease: Phase 3 Study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_15","first-page":"5","article-title":"A Systematic Review and Meta-Analysis of 18F-Labeled Amyloid Imaging in Alzheimer\u2019s Disease","volume":"1","author":"Yeo","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","article-title":"Defining a Centiloid Scale Threshold Predicting Long-Term Progression to Dementia in Patients Attending the Memory Clinic: An [18F] Flutemetamol Amyloid PET Study","volume":"48","author":"Hanseeuw","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103765","DOI":"10.1016\/j.nicl.2025.103765","article-title":"A Practical Overview of the Use of Amyloid-PET Centiloid Values in Clinical Trials and Research","volume":"46","author":"Iaccarino","year":"2025","journal-title":"Neuroimage Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2967\/jnumed.115.171595","article-title":"Standardized Expression of 18F-NAV4694 and 11C-PiB \u03b2-Amyloid PET Results with the Centiloid Scale","volume":"57","author":"Rowe","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1002\/alz.13761","article-title":"Investigating Reliable Amyloid Accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study","volume":"20","author":"Bollack","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39963","DOI":"10.1038\/s41598-025-23759-5","article-title":"Concordance between Amyloid PET and CSF Biomarkers in Clinical Setting: A Cross-Platform Comparison and in-Depth Analysis of Discordant Cases","volume":"15","author":"Cerman","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2967\/jnumed.124.268119","article-title":"Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study","volume":"66","author":"Collij","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) Phase 1b Study in Alzheimer\u2019s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100008","DOI":"10.1016\/j.tjpad.2024.100008","article-title":"Expert Opinion on Centiloid Thresholds Suitable for Initiating Anti-Amyloid Therapy. Summary of Discussion at the 2024 Spring Alzheimer\u2019s Association Research Roundtable","volume":"12","author":"Farrar","year":"2025","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Matsuda, H., Ito, K., Ishii, K., Shimosegawa, E., Okazawa, H., Mishina, M., Mizumura, S., Ishii, K., Okita, K., and Shigemoto, Y. (2021). Quantitative Evaluation of 18F-Flutemetamol PET in Patients with Cognitive Impairment and Suspected Alzheimer\u2019s Disease: A Multicenter Study. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.578753"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","article-title":"Centiloid Cut-off Values for Optimal Agreement between PET and CSF Core AD Biomarkers","volume":"11","author":"Molinuevo","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1002\/alz.13883","article-title":"Stress Testing the Centiloid: Precision and Variability of PET Quantification of Amyloid Pathology","volume":"20","author":"Shekari","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1212\/WNL.0000000000205923","article-title":"Impact of Clinical Subgroup and Baseline Amyloid PET Centiloid Levels on Occurrence of ARIA in the Lecanemab Phase 3 Clarity AD Study in Early Alzheimer\u2019s Disease (P1-9.007)","volume":"102","author":"Sabbagh","year":"2024","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e213483","DOI":"10.1212\/WNL.0000000000213483","article-title":"Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-\u03b2 Immunotherapy","volume":"104","author":"Jeong","year":"2025","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-Related Imaging Abnormalities with Donanemab In Early Symptomatic Alzheimer Disease","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2967\/jnmt.125.271835","article-title":"PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape","volume":"54","author":"Skyles","year":"2026","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Iizuka, T., Watanabe, T., and Kameyama, M. (2026). Aging Modulates Amyloid Clearance Kinetics during Anti-Amyloid Therapy: Evidence from Real-World Serial Amyloid PET. Front. Aging Neurosci., 18.","DOI":"10.3389\/fnagi.2026.1801267"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bhargava, V., Wang, M., Chen, Y., Luo, J., Weiner, M., Landau, S., Jagust, W., Sabbagh, M., Su, Y., and Reiman, E. (2025). Impact of a White Matter Reference Region on the Relationship between Florbetapir PET Measurements of Amyloid Plaque Deposition and Measurements of Cognitive Decline. medRxiv, 2025.09.19.25336123.","DOI":"10.1101\/2025.09.19.25336123"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40658-019-0258-7","article-title":"Spill-in Counts in the Quantification of 18F-Florbetapir on A\u03b2-Negative Subjects: The Effect of Including White Matter in the Reference Region","volume":"6","author":"Moscoso","year":"2019","journal-title":"EJNMMI Phys."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21300\/18.1.2016.5","article-title":"Reducing CSF Partial Volume Effects to Enhance Diffusion Tensor Imaging Metrics of Brain Microstructure","volume":"18","author":"Salminen","year":"2016","journal-title":"Technol. Innov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"118248","DOI":"10.1016\/j.neuroimage.2021.118248","article-title":"Partial Volume Correction Analysis for 11C-UCB-J PET Studies of Alzheimer\u2019s Disease","volume":"238","author":"Lu","year":"2021","journal-title":"Neuroimage"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wang, J., Bermudez, D., Chen, W., Durgavarjhula, D., Randell, C., Uyanik, M., and McMillan, A. (2024). Motion-Correction Strategies for Enhancing Whole-Body PET Imaging. Front. Nucl. Med., 4.","DOI":"10.3389\/fnume.2024.1257880"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.neuroimage.2009.01.057","article-title":"Reducing between Scanner Differences in Multi-Center PET Studies","volume":"46","author":"Joshi","year":"2009","journal-title":"Neuroimage"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2967\/jnumed.118.211532","article-title":"Assessing Amyloid Pathology in Cognitively Normal Subjects Using 18F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods","volume":"60","author":"Collij","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3\u201345 Study: Design of a Prevention Trial for Alzheimer\u2019s Disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal Clinically Important Difference in Alzheimer\u2019s Disease: Rapid Review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"fcad276","DOI":"10.1093\/braincomms\/fcad276","article-title":"Responder Analyses for Anti-Amyloid Immunotherapies for Alzheimer\u2019s Disease: A Paradigm Shift by Regulatory Authorities Is Urgently Needed","volume":"5","author":"Salemme","year":"2023","journal-title":"Brain Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1002\/alz.14050","article-title":"Care Partner-Informed Meaningful Change Thresholds for the Clinical Dementia Rating-Sum of Boxes for Trials of Early Alzheimer\u2019s Disease","volume":"20","author":"Lansdall","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14283\/jpad.2022.102","article-title":"Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer\u2019s Disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1093\/brain\/awaf033","article-title":"Plasma Phosphorylated Tau217 Strongly Associates with Memory Deficits in the Alzheimer\u2019s Disease Spectrum","volume":"148","author":"Brum","year":"2025","journal-title":"Brain"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/alz.12875","article-title":"Tau-PET Is Superior to Phospho-Tau When Predicting Cognitive Decline in Symptomatic AD Patients","volume":"19","author":"Smith","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_49","unstructured":"U.S. Food and Drug Administration (2023). Summary Review."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13195-024-01412-z","article-title":"The Search for Clarity Regarding \u201cClinically Meaningful Outcomes\u201d in Alzheimer Disease Clinical Trials: CLARITY-AD and Beyond","volume":"16","author":"Tarawneh","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_51","first-page":"e12617","article-title":"Plasma P-Tau217 Concordance with Amyloid PET among Ethnically Diverse Older Adults","volume":"16","author":"Asken","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_52","first-page":"1797","article-title":"Plasma P-Tau231 and p-Tau217 as State Markers of Amyloid-\u03b2 Pathology in Preclinical Alzheimer\u2019s Disease","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3233\/JAD-230744","article-title":"Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer\u2019s Disease","volume":"97","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised Criteria for Diagnosis and Staging of Alzheimer\u2019s Disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2967\/jnumed.124.268756","article-title":"Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"66","author":"Rabinovici","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e14528","DOI":"10.1002\/alz.14528","article-title":"Considerations in the Clinical Use of Amyloid PET and CSF Biomarkers for Alzheimer\u2019s Disease","volume":"21","author":"Leuzy","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood Biomarkers for Alzheimer\u2019s Disease in Clinical Practice and Trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"ref_58","unstructured":"U.S. Food and Drug Administration (2025). KISUNLA (Donanemab-Azbt) Injection, for Intravenous Use: Full Prescribing Information."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e70293","DOI":"10.1002\/alz.70293","article-title":"TRAILBLAZER-ALZ 4: A Phase 3 Trial Comparing Donanemab with Aducanumab on Amyloid Plaque Clearance in Early, Symptomatic Alzheimer\u2019s Disease","volume":"21","author":"Salloway","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e70197","DOI":"10.1111\/ene.70197","article-title":"Utility, Costs and Cost-Utility of Amyloid-PET in the Diagnostic Process of Memory Clinic Patients: A Trial-Based Economic Evaluation From AMYPAD-DPMS","volume":"32","author":"Altomare","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e110090","DOI":"10.1002\/alz70862_110090","article-title":"Interchangeability of Centiloid Values from Different Research and Commercial Software Using [18F]Flutemetamol PET Images","volume":"21","author":"Bollack","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_62","unstructured":"Centers for Medicare & Medicaid Services (2023). NCA\u2014Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431R)\u2014Decision Memo."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.14283\/jpad.2024.81","article-title":"Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer\u2019s Treatments with Different Duration and Route of Administration","volume":"11","author":"Ozawa","year":"2024","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e70997","DOI":"10.1002\/alz.70997","article-title":"Treatment-related Amyloid Clearance (TRAC): A Framework to Characterize Patients in the Era of Anti-amyloid Therapies","volume":"21","author":"Cummings","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e099404","DOI":"10.1002\/alz70856_099404","article-title":"Changes in Alzheimer\u2019s Disease Blood Biomarkers in Patients Undergoing Lecanemab Therapy","volume":"21","author":"Bornhorst","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e70763","DOI":"10.1002\/alz.70763","article-title":"Complementary Utility of Plasma Biomarkers and A\u03b2-PET for Diagnosis, Risk-Stratification, and Treatment Monitoring in Alzheimer\u2019s Disease","volume":"21","author":"Collij","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13195-024-01521-9","article-title":"Clinical Application of Plasma P-Tau217 to Assess Eligibility for Amyloid-Lowering Immunotherapy in Memory Clinic Patients with Early Alzheimer\u2019s Disease","volume":"16","author":"Howe","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e105473","DOI":"10.1002\/alz70856_105473","article-title":"Can Longitudinal Measures of Plasma Biomarkers Track Disease Progression in Early Alzheimer\u2019s Disease?","volume":"21","author":"Bali","year":"2026","journal-title":"Alzheimer\u2019s Dement."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/1989\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:31:08Z","timestamp":1782466268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/1989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":68,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["diagnostics16131989"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16131989","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}